What is HC Wainwright's Estimate for ZVRA FY2027 Earnings?

Key Points

• HC Wainwright raised its FY2027 EPS forecast for Zevra Therapeutics to $0.66 from $0.55. It maintains a Buy rating and a $26 price target; the analyst consensus estimate is $0.72 per share.
• Zevra’s Q3 2026 revenue increased 45% year over year to $37.8 million, and the company beat earnings estimates for a fourth consecutive quarter.
• The company expects to file a supplemental application for MIPLYFFA in Q1 2027, while a European regulatory opinion on the drug is still expected in Q4.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Zevra Therapeutics in a report released on Wednesday, November 4th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.66 per share for the year, up from their prior forecast of $0.55. HC Wainwright currently has a "Buy" rating and a $26.00 target price on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is $0.72 per share.

ZVRA has been the topic of several other research reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th. Wall Street Zen raised shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Sunday, July 12th. Guggenheim decreased their price target on shares of Zevra Therapeutics from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Citizens Jmp upped their price target on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a "market outperform" rating in a research note on Thursday, August 6th. Finally, BTIG Research lowered their price target on shares of Zevra Therapeutics from $27.00 to $24.00 and set a "buy" rating on the stock in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $27.14.

Zevra Therapeutics Trading Up 8.9%

NASDAQ:ZVRA opened at $11.17 on Thursday. The stock has a 50 day simple moving average of $11.10 and a 200 day simple moving average of $10.76. The stock has a market cap of $663.27 million, a P/E ratio of 9.39 and a beta of 1.01. Zevra Therapeutics has a 1-year low of $8.01 and a 1-year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. The company had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 57.91% and a net margin of 52.80%.

Insider Activity at Zevra Therapeutics

In related news, Director Corey Watton sold 12,300 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $11.25, for a total transaction of $138,375.00. Following the sale, the director owned 1,800 shares of the company's stock, valued at $20,250. This represents a 87.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Neil McFarlane sold 20,000 shares of the stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $11.25, for a total value of $225,000.00. Following the sale, the chief executive officer directly owned 417,225 shares in the company, valued at $4,693,781.25. This represents a 4.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.70% of the company's stock.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new position in shares of Zevra Therapeutics in the second quarter worth $28,000. Fulcrum Asset Management LLP acquired a new position in Zevra Therapeutics in the third quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Zevra Therapeutics in the third quarter valued at about $33,000. State of Alaska Department of Revenue bought a new stake in Zevra Therapeutics during the third quarter worth about $44,000. Finally, State of Wyoming bought a new stake in Zevra Therapeutics during the third quarter worth about $81,000. 35.03% of the stock is currently owned by institutional investors.

Key Stories Impacting Zevra Therapeutics

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q3 2026 revenue rose 45% year over year to $37.8 million, including $34.0 million from MIPLYFFA. Earnings also beat analyst estimates, and the company marked a fourth consecutive quarterly earnings beat. Zevra Q3 financial results and corporate update Zevra beats Q3 estimates for fourth straight quarter
• Positive Sentiment: Zevra expects to file a supplemental new drug application for MIPLYFFA in Q1 2027, a potential future growth opportunity. Zevra anticipates filing MIPLYFFA sNDA in Q1 2027
• Neutral Sentiment: A European CHMP opinion on MIPLYFFA remains expected in Q4; the regulatory outcome is still pending. Regulatory timeline update

About Zevra Therapeutics

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra's lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.